Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced that the first patient has been dosed in the Phase 3 clinical program of its investigational therapy BIVV009 for cold agglutinin disease (CAgD). The Phase 3 program includes two parallel Phase 3 trials, Cardinal and Cadenza, which are evaluating the efficacy and safety of BIVV009 in adult patients with primary CAgD, a disease with no approve...
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced the publication of a retrospective analysis investigating the use of ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for immune tolerance induction (ITI). These data add to a growing body of evidence supporting the potential of ELOCTATE to induce tolerance in severe hemophilia A patients with inhibitors. This analysis was ...
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) today reported financial results for the fourth quarter and full year of 2017. Key financial results include: Fourth quarter 2017 revenues of $328.7 million, up 28.3% year-over-year Fourth quarter 2017 revenues increased $37.1 million over third quarter 2017, up 12.7% Fourth quarter 2017 GAAP net income of $141.3 million; Non-GAAP net income of $103.3 million Full year 2017 GAAP tax...
On January 22, 2018, Sanofi (NYSE: SNY, $45.32, Market Capitalization: $114.5 billion) and Bioverativ (NASDAQ: BIVV, $102.90, Market Capitalization: $11.1 billion) announced a definite agreement under which Sanofi will acquire all of the outstanding shares of BIVV for $105 per share in cash, representing ~64% premium to the closing price on January 19, 2018. The deal represents an equity value of ~$11.6 billion (on a fully diluted basis). The transaction has been unanimously approved by the Bo...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Bioverativ Inc. (“Bioverativ” or the “Company”) (NASDAQGS:BIVV) stock prior to January 22, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Bioverativ Inc. to Sanofi for $105 per share. To learn more about the action and your rights, go to: http://www.zlk.com/mna/bioverativ-inc or ...
Sanofi announced the acquisition of Bioverativ for $11.6 billion ($105 per share), well ahead of our $49.50 stand-alone valuation of the company and we expect to slightly lower our fair value estimate for Sanofi. However, we continue to view Sanofi’s wide moat as intact, as the overpayment is relatively small compared with the overall size of Sanofi. We believe near-term core earnings support (excludes amortization costs), the ability to geographically expand Bioverativ’s key drugs into emer...
NEW YORK--(BUSINESS WIRE)-- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Bioverativ Inc. (NASDAQ:BIVV) stockholders concerning the proposed acquisition of the company by Sanofi (NYSE:SNY) Our investigation concerns whether Bioverativ’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Sanofi. Under the terms of the agreement, Bioverativ stockholders will receive $105 per share in...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Bioverativ Inc. (NASDAQ GS: BIVV)? Did you purchase any of your shares prior to January 22, 2018? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Bioverativ Inc. (“Bioverativ” or the “Company”) (NASDAQ GS: BIVV) regarding...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Bioverativ Inc. (“Bioverativ” or the “Company”) (NASDAQGS:BIVV) stock prior to January 22, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Bioverativ Inc. to Sanofi for $105 per share. To learn more about the action and your rights, go to: http://www.zlk.com/mna/bioverativ-inc or ...
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) today announced it will report fourth quarter and year-end 2017 financial results on Tuesday, February 13, 2018, after the market closes. The press release will be available in the “Investor Relations” section of the company’s website at investors.bioverativ.com. On Wednesday, February 14, 2018, at 8:00 a.m. EST, the company will host a live webcast with Bioverativ management. To access the live webcast, please visit Bioverativ’s Investors page at investors.biov...
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at the 2018 J.P. Morgan Healthcare Conference. The event will be webcast live on Monday, January 8, 2018 at 4:00 p.m. PST. To access the live webcast, please visit Bioverativ’s Investors page at investors.bioverativ.com. An archived version of the webcast will be available following the presentation. About BioverativBioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of p...
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, announced today that its 2018 Annual Meeting of Stockholders has been scheduled for April 25, 2018. Additional information concerning the 2018 Annual Meeting will be included in Bioverativ’s 2018 Annual Meeting proxy statement, which will be filed with the SEC and mailed to Bioverativ’s stockholders at a later date. Stockholders intending to presen...
We may modestly lower our fair value estimates for hemophilia incumbents Shire, Sobi, and Bioverativ following Roche’s positive Hemlibra data in the broader, non-inhibitor hemophilia A population. Hemlibra was approved by the FDA last week for inhibitor patients (affecting Shire’s Feiba) and has now shown superior control of bleeds in the general, non-inhibitor hemophilia A population ($6 billion market) when administered subcutaneously once weekly, over prior intravenous factor VIII prophyl...
ATLANTA--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today presented data demonstrating that BIVV009, its first-in-class monoclonal antibody currently in Phase 3 clinical development for the treatment of cold agglutinin disease (CAgD), was generally well tolerated, rapidly halted hemolysis, and improved anemia in six of six severely anemic primary CAgD patients in a Phase 1b clinical trial. The data were shared in a...
ATLANTA--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ:BIVV) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced the results of a new, post-hoc longitudinal analysis demonstrating that individualized dosing with extended half-life therapy, ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein], every 14 or more days may be a potential option for people with severe hemophilia B who seek the benefits of protection from a prophylactic therapy with reduced treatment burden. The analysis is being presen...
ATLANTA--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announce the results of a new, post-hoc, longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE long-term extension study, showing that weekly prophylactic dosing with its extended half-life therapy ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein], marketed as Elocta® in Europe and the Middle East, has the potential to provide improved bleed protection over episodic treatment,...
ATLANTA--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced findings from a novel imaging study investigating extravascular distribution of factor IX therapies, including its leading extended half-life therapy, ALPROLIX® [Antihemophilic Factor IX (Recombinant), Fc Fusion Protein]. The preclinical study showed ALPROLIX had a higher level of extravascular distribution and retention in certain joint areas when...
WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the leading extended half-life therapy for the treatment of adults and children with hemophilia B. The label update, including the addition of pediatric data showing prophylactic treatment wit...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.